Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ
Authors
Keywords
-
Journal
HISTOPATHOLOGY
Volume 71, Issue 2, Pages 258-268
Publisher
Wiley
Online
2017-03-23
DOI
10.1111/his.13217
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes
- (2016) Ahrong Kim et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast
- (2016) Michael J. Campbell et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score
- (2015) Adriana Knopfelmacher et al. MODERN PATHOLOGY
- Unknown
- (2015) Huan Yang et al. MOLECULAR MEDICINE
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) J. R. Brown et al. CLINICAL CANCER RESEARCH
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
- (2014) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Ductal carcinomain situof the breast: morphological and molecular features implicated in progression
- (2013) Dirce M. Carraro et al. BIOSCIENCE REPORTS
- Clinical evaluation of systemic and local immune responses in cancer: time for integration
- (2013) Dmitriy W. Gutkin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of v 6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence
- (2013) M. D. Allen et al. CLINICAL CANCER RESEARCH
- Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinomain situ
- (2013) Hitchintan Kaur et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study
- (2013) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- CD4+ follicular helper T cell infiltration predicts breast cancer survival
- (2013) Chunyan Gu-Trantien et al. JOURNAL OF CLINICAL INVESTIGATION
- High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin -Producing Dendritic Cells in Human Breast Cancer
- (2013) L. Martinet et al. JOURNAL OF IMMUNOLOGY
- Progression from ductal carcinoma in situ to invasive breast cancer: Revisited
- (2013) Catherine F. Cowell et al. Molecular Oncology
- Tumor-infiltrating B cells and T cells
- (2012) Julie S. Nielsen et al. OncoImmunology
- Lymphocyte deficiency limits Epstein-Barr virus latent membrane protein 1 induced chronic inflammation and carcinogenic pathology in vivo
- (2011) Adele Hannigan et al. Molecular Cancer
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
- (2011) V. N. Kristensen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leukocyte composition of human breast cancer
- (2011) B. Ruffell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study
- (2011) Cathy B. Moelans et al. CELLULAR ONCOLOGY
- Different Distribution of Breast Cancer Subtypes in Breast Ductal Carcinoma in situ (DCIS), DCIS with Microinvasion, and DCIS with Invasion Component
- (2010) Ke-Da Yu et al. ANNALS OF SURGICAL ONCOLOGY
- The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study
- (2010) So-Youn Jung et al. BMC CANCER
- MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
- (2010) Mohammed A. Aleskandarany et al. BREAST CANCER RESEARCH AND TREATMENT
- CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
- (2010) B. H. Nelson JOURNAL OF IMMUNOLOGY
- Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
- (2009) M. Gobert et al. CANCER RESEARCH
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started